Navigation Links
New evidence explains poor infant immune response to certain vaccines, says MU researcher
Date:4/1/2009

COLUMBIA, Mo. For years, researchers and physicians have known that infants' immune systems do not respond well to certain vaccines, thus the need for additional boosters as children develop. Now, in a new study from the University of Missouri, one researcher has found an explanation for that poor response. In the study, the MU scientist found evidence that the immune systems of newborns might require some time after birth to mature to a point where the benefits of vaccines can be fully realized.

Habib Zaghouani, a professor of molecular microbiology and immunology and child health at the MU School of Medicine, recently found that a slowly maturing component of the immune system might explain why newborns contract infections easily. In his work, Zaghouani studied newborn mice and how their immune systems reacted when they were repeatedly exposed to an antigen that simulates a virus.

Zaghouani found that while the antigen would prompt a response of the immune system, it was not the expected response. In the adult immune system, two major types of cells, known as T-helper 1 (Th-1) and T-helper 2 (Th-2) cells, are instrumental in the development of an effective immune response. Typically, Th-1 cells respond when dangerous microbes enter the body. The Th-1 cells then work to help destroy the foreign microbes. When an antigen from a vaccine enters a body with a mature immune system, Th-1 cells respond and, after destroying the invader, the Th-1 cells "remember" how to fight the antigen for future battles. Th-2 cells typically develop when the body is exposed to allergens. The responses of Th-2 cells are usually strong and manifest in the form of allergic reactions.

When Zaghouani gave the newborn mice an antigen shortly after birth, he noticed the presence of both Th-1 and Th-2 cells. However, when he gave the antigen a second time, he noticed an abundance of Th-2 cells that responded to the antigen instead of Th-1 cells. Zaghouani was surprised to notice that the Th-2 cells worked to destroy the small contingent of Th-1 cells that had responded to the antigen given at birth.

"Perhaps we should test vaccines at a very early age in animals to establish a regimen with the most effectiveness," Zaghouani said.

When a baby first gets an infection, the immature immune system responds with both types of T cells. Unfortunately, Th-1 cells have an unusual receptor that binds to a specific hormone, which is deadly to the Th-1 cells. Ironically, this particular hormone is produced by the Th-2 cells. This results in an overabundance of Th-2 cells during the first few days of life.

"We found that after six days, the immune systems in the mice matured enough to stop the death of the Th-1 cells," Zaghouani said. "After those initial days, the immune system is producing Th-1 cells with diminished hormonal receptors, thus surviving the effect of the compound that the Th-2 cells make."


'/>"/>

Contact: Christian Basi
BasiC@missouri.edu
573-882-4430
University of Missouri-Columbia
Source:Eurekalert

Related biology news :

1. A private bandwidth for communication in bats: Evidence from insular horseshoe bats
2. Comet probes reveal evidence of origin of life, scientists claim
3. Evidence of a relationship between swimming babies and infections
4. Researchers find evidence linking stress caused by the Sept. 11 disaster with low birth weights
5. Fossil record supports evidence of impending mass extinction
6. New evidence for female control in reproduction
7. RAND study finds evidence disease management programs
8. CWRU School of Medicine has evidence vaccine against malaria will reduce disease
9. There is powerful evidence of evolution in human DNA
10. Scientific evidence supporting evolution continues to grow
11. No convincing evidence for decline in tropical forests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2016)... NEW YORK , December 22, 2016 ... global provider of secure solutions for the e-Government, Public Safety, HealthCare, ... a subsidiary of SuperCom, has been selected to implement and deploy ... county in Northern California , further expanding its ... ...
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL ... desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar ... 2017, con múltiples sitios previstos a lo largo de Europa y ... MSC-1 es ... inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ...
(Date:12/16/2016)... The global wearable medical device market, in terms of value, is ... billion in 2016, at a CAGR of 18.0% during the forecast ... Growth ... devices, launch of a growing number of smartphone-based healthcare apps compatible ... and increasing focus on physical fitness. Furthermore, growing ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... India , January 24, 2017 According to ... Culture, Cell Expansion, Cell Counting, Cell Line Development, Flow Cytometry, Single-Use Bioprocessing, ... to 2021", published by MarketsandMarkets, the global market is expected to reach ... a CAGR of 12.4% from 2016 to 2021. ... ...
(Date:1/24/2017)... Calif. , Jan. 24, 2017  Asterias ... pioneering the field of regenerative medicine, today announced ... Phase 1/2a clinical trial that showed additional motor ... of 10 million AST-OPC1 cells in AIS-A patients ... "Recovery of upper extremity motor function is ...
(Date:1/24/2017)... ... January 24, 2017 , ... Nanomedical ... assays for fragment-based screening, will showcase its proprietary Field Effect Biosensing ... and Screening (SLAS) conference in Washington, D.C. from Feb. 6 to Feb. 8. ...
(Date:1/24/2017)... , ... January 23, 2017 , ... ... supports innovative science through unique partnerships, seeks outstanding early career nominees for the ... is critical to meeting the needs of a world in which one in ...
Breaking Biology Technology: